Jeff Cerny
Analyst · Ladenburg. Please go ahead
Thanks and good morning, everyone. As Bilal mentioned, our third quarter was highlighted by our net investment income exceeding our distribution, an increase in our net asset value per share, and capital deployment of $47.4 million. Starting with the income statement, for the third quarter we derived approximately $11 million in total investment income, a $700,000 increase over the second quarter. Net investment income increased to $0.35 per share compared to $0.34 in the prior quarter. The increase was primarily driven by an increase in investment assets including, a full quarter of earnings from the strong deployment in the second quarter and continued deployment in the third quarter. Total expenses of $6.3 million increased compared to $5.7 million in the prior quarter. This increase was most notably driven by higher interest expense due to a full quarter of interest on the bonds we issued in the April 2018 offering along with a higher outstanding line of credit balance used to fund additional originations. Turning to the balance sheet. Our net asset value at the end of the quarter was up $0.05 to $13.75 per share. At the end of the quarter, we had approximately $6 million of cash of which $5 million was in our SBIC, plus $33 million in availability on our line of credit. As Bilal mentioned, we closed a bond offering in October, totaling approximately $46 million, which included a partial exercise of the underwriters' overallotment option. An addition of $2.5 million was issued this week and OFS may issue up to another $1.5 million pursuant to the underwriters' overallotment option on or before November 10. We used $31 million of the bond proceeds to repay our line of credit, leaving us with the full $50 million of availability on this line. In May, our Board authorized the share repurchase program. We think it is important to have an active program in place. We've been monitoring the recent weakness in the broader market and/or of our shares and we intend to utilize the program opportunistically. Our debt-to-equity ratio at the end of the quarter was about 1.2x including our SBIC debt. This is well below our regulatory leverage requirements as the SBIC debt does not count towards a leverage test. Over time we would be comfortable increasing our leverage further. Turning to the portfolio. At the end of the quarter, we had investments in 47 companies totaling $396 million on a fair value basis. As a percentage of cost or investments, were approximately 73% senior secured loans, 19% subordinated debt, and 8% equity, two-thirds of which is in preferred securities. Our portfolio remains diversified with an average investment in each portfolio of company of $8.4 million or 2.1% of the portfolio's total fair value. At fair value we currently have 0.4% of the portfolio on non-accrual, compared to 0.6% last quarter. The overall weighted average yield to cost on our performing debt investments was 12.1% at September 30. This compares to a weighted average cost on our borrowings of just 4.5% at quarter's end. We deployed $47.3 million in the third quarter across 11 investments. This consisted of $9.1 million in increases to several existing portfolio of companies, and we also invested $38.2 million in six new names. The new names consisted mostly of floating rate and senior secured loans with a weighted average yield on new debt investments of 11%. One of the quarter's new investments was a floating rate senior secured loan facility that we closed with JBR Clinical Research. JBR has a 30 plus year operating history as a site manager for pharmaceutical trials, providing industry leading study, design, and management. The OFS team directly sourced and underwrote the, leveraging both internal diligence efforts and third party expert resources to underwrite and structure the deal. We ultimately closed the transaction with a full covenant package and board observation rights. As Bilal noted, we believe we are well positioned in a rising rate environment. With our asset and liability profile at quarter's end, for each 50 basis points of LIBOR increase we realize an organic per share increase of $0.027 per quarter after the impact of incentive fees or a 7.7% increase in quarterly net investment income. We believe our increased capital base continues to provide us additional flexibility and capacity to make larger investments, and our bond offering in the fourth quarter continues to improve that flexibility. Also as you may recall in May 2018, our Board approved a reduction in the asset coverage ratio under the 1940 Act, which will permit increased leverage for our BDC as soon as this coming May. With that, I will turn the call back over to Bilal.